GSK Terminates Development of HBV Therapeutic Vaccine Due to Efficacy Failure

Termination of HBV Vaccine Trial:
GSK has halted the development of its therapeutic vaccine for hepatitis B virus (HBV) after it failed to meet the predefined efficacy endpoint in a Phase 2 clinical trial35.

Efficacy Miss:
The vaccine candidate, GSK3528869, did not achieve the necessary efficacy results, leading to the termination of the trial35.

Continued Research:
Despite this setback, GSK remains committed to advancing research and development efforts in the field of infectious diseases, including HBV.

Broader Context:
The failure of GSK's HBV vaccine trial highlights the challenges in developing effective treatments for chronic hepatitis B, a condition with significant unmet medical needs.

Other Developments:
GSK has also faced setbacks in other vaccine development programs, including the recent halt of its herpes simplex virus (HSV) vaccine trial due to efficacy concerns12.

Sources:

1. https://www.investing.com/news/company-news/gsk-halts-hsv-vaccine-trial-as-phase-ii-misses-efficacy-goals-93CH-3611137

2. https://synapse.patsnap.com/article/gsk-halts-herpes-vaccine-after-phase-2-failure

3. https://endpts.com/gsk-terminates-phase-2-trial-of-hbv-therapeutic-vaccine/

5. https://www.fiercebiotech.com/biotech/gsk-axes-hepatitis-b-vaccine-trial-after-missing-efficacy-goal